Drug Profile


Alternative Names: Lorexys; Orexa; S1P-104; S1P-205; SIP-104; Trazodone/bupropion

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator S1 Pharmaceuticals
  • Developer S1 Biopharma
  • Class Erectile dysfunction therapies; Piperazines; Propiophenones; Pyridones; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha adrenergic receptor agonists; Dopamine uptake inhibitors; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Sexual function disorders

Highest Development Phases

  • Phase II Female sexual dysfunction
  • Preclinical Male sexual dysfunction

Most Recent Events

  • 12 Sep 2016 Preclinical development is ongoing in USA (S1 Biopharma pipeline, September 2016)
  • 12 Sep 2016 Phase-II clinical trials in Female sexual dysfunction in USA (PO) before September 2016 (S1 Biopharma pipeline)
  • 08 Dec 2015 Bupropion/trazodone licensed to CKD Pharmaceuticals in South Korea for commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top